AbbVie posted a Phase 3 win for lutikizumab in a painful skin condition and indicated an FDA filing timeline likely to land next year. The company’s IL-1α/IL-1β inhibitor results add another late-stage data point for cytokine-targeting strategies that aim to translate biomarker-driven biology into durable responder rates. Roche also signaled confidence in its broader strategy after discussing Phase 3 success rate performance while unveiling pipeline cuts. The pairing of late-stage progress and portfolio reshaping reflects a sharpened approach to capital allocation amid a summer of high-profile failures across Europe’s big pharma. Together, the updates show developers doubling down on immunology targets with clearer clinical signals while simultaneously trimming programs that don’t meet internal expectations for probability-weighted value.